U.S. Scientists demonstrate efficacy of VM202

Published: 2008-09-19 06:20:00

Updated: 2008-09-19 06:20:00

A team of the U.S. scientists have discovered that VM202, a newly constructed plasmid human hepatocyte growth factor, improved myocardial perfusion, viability, and LV function in pigs, opening new possibilities for treatment of coronary artery disease (CAD).

The University of California team, ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK